Dolutegravir/Abacavir/Lamivudine Versus Current ART in Virally Suppressed Patients (STRIIVING): A 48-Week, Randomized, Non-Inferiority, Open-Label, Phase IIIb Study

Antiviral Therapy - United Kingdom
doi 10.3851/imp3166

Related search